Back to top
more

UiPath (PATH)

(Delayed Data from NYSE)

$12.00 USD

12.00
13,482,820

-0.25 (-2.04%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $11.98 -0.02 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 248)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PATH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

[PATH]

Reports for Purchase

Showing records 101 - 120 ( 129 total )

Industry: Medical - Products

Record: 101

10/09/2012

Company Report

Pages: 9

Cost Containment Extends Runway To YE 2013

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 102

09/26/2012

Company Report

Pages: 10

Private Placement Extends Cash Runway Guidance To Mid- 2013. Reiterate OUTPERFORM But Reducing FV To $7 For Dilution

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 103

08/30/2012

Industry Report

Pages: 20

September and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 104

08/19/2012

Company Report

Pages: 9

Q2 Financials In Line; Cash Runway Guidance Is To The End Of Q3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 105

08/06/2012

Industry Report

Pages: 17

August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 106

07/31/2012

Daily Note

Pages: 7

Zelrix NDA Accepted For FDA Review; PDUFA on January 17, 2013; Partnership Announcement Could Be Next

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 107

07/27/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 108

07/25/2012

Daily Note

Pages: 7

New CEO Is Industry Veteran

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 109

07/20/2012

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 110

07/16/2012

Daily Note

Pages: 7

Zelrix NDA Resubmitted

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 111

07/06/2012

Industry Report

Pages: 17

Emerging Pharmaceuticals - July and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 112

07/02/2012

Daily Note

Pages: 7

Slight Delay for Zelrix NDA Resubmission not Material, in Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 113

06/21/2012

Daily Note

Pages: 7

Additional Zelrix Analyses Presented at American Headache Society Conference Reinforces Safety

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 114

06/03/2012

Industry Report

Pages: 19

Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 115

05/10/2012

Company Report

Pages: 9

Q1 Financials: Slightly Higher Spending On CRL Requirements But Cash Runway Extends Past NDA Resubmission. Reiterate OUTPERFORM And $18 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 116

03/30/2012

Industry Report

Pages: 20

Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 117

03/20/2012

Company Report

Pages: 9

Q4 Financials Were Uneventful And Cash Runway Extends Past NDA Resubmission. Reiterate OUTPERFORM Rating And Increasing FV To $18 For Time Value.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 118

02/29/2012

Daily Note

Pages: 7

US Patent Allowance For NP202 Opens Door For NuPathe''s Second Platform. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 119

02/13/2012

Daily Note

Pages: 7

Corporate Update: We Estimate NDA Resubmission Is More Likely in Q2. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 120

01/22/2012

Industry Report

Pages: 25

Ue with Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party